Loading...
Loading...
SRRK| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 64.8M |
| Operating I/L | -64.8M |
| Other Income/Expense | 0.3M |
| Interest Income | 0.0M |
| Pretax | -64.5M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -64.5M |
Scholar Rock Holding Corporation is a biopharmaceutical company specializing in the discovery and development of medicines targeting protein growth factor signaling for serious diseases. Its lead product, Apitegromab, is an inhibitor of latent myostatin activation, completing Phase 3 trials for spinal muscular atrophy. Additionally, SRK-181, in Phase 1 trials, aims to treat cancers resistant to checkpoint inhibitor therapies. The company's pipeline includes novel candidates for neuromuscular disorders, cancer, and fibrosis. Collaborating with Gilead Sciences, Inc., it focuses on discovering and developing specific inhibitors of transforming growth factor beta activation for fibrotic disease treatment.
